image credit: Freepik

Hemogenyx Pharmaceuticals PLC Announces Update on CDX Antibody Development

January 13, 2021

Via: BioSpace

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”). As a result of the Company’s successful collaboration with GlobalCo, the Company has chosen a clone of its CDX antibody that is ready for investigational new drug (“IND”) application-enabling studies, a significant step toward clinical trials.

Read More on BioSpace